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Background: M3 and M1 subtype muscarinic receptors are co-expressed in normal and neoplastic intestinal epithelial
cells. In mice, ablating Chrm3, the gene encoding M3R, robustly attenuates intestinal tumor formation. Here we
investigated the effects of Chrm1 gene ablation, alone and in combination with Chrm3 ablation.
Methods: We used wild-type, Chrm1-/-, Chrm3-/- and combined Chrm1-/-/Chrm3-/- knockout (dual knockout) mice.
Animals were treated with azoxymethane, an intestine-selective carcinogen. After 20 weeks, colon tumors were
counted and analyzed histologically and by immunohistochemical staining. Tumor gene expression was analyzed using
microarray and results validated by RT-PCR. Key findings were extended by analyzing gene and protein expression in
human colon cancers and adjacent normal colon tissue.
Results: Azoxymethane-treated Chrm3-/- mice had fewer and smaller colon tumors than wild-type mice. Reductions in
colon tumor number and size were not observed in Chrm1-/- or dual knockout mice. To gain genetic insight into these
divergent phenotypes we used an unbiased microarray approach to compare gene expression in tumors from Chrm3-/-
to those in wild-type mice. We detected altered expression of 430 genes, validated by quantitative RT-PCR for the top
14 up- and 14 down-regulated genes. Comparing expression of this 28-gene subset in tumors from wild-type, Chrm3-/-,
Chrm1-/- and dual knockout mice revealed significantly reduced expression of Zfp277, encoding zinc finger protein 277,
in tissue from M3R-deficient and dual knockout mice, and parallel changes in Zfp277 protein expression. Notably,
mRNA and protein for ZNF277, the human analogue of Zfp277, were increased in human colon cancer compared to
adjacent normal colon, along with parallel changes in expression of M3R.
Conclusions: Our results identify a novel candidate mouse gene, Zfp277, whose expression pattern is compatible with
a role in mediating divergent effects of Chrm3 and Chrm1 gene ablation on murine intestinal neoplasia. The biological
importance of this observation is strengthened by finding increased expression of ZNF277 in human colon cancer with
a parallel increase in M3R expression. The role of zinc finger protein 277 in colon cancer and its relationship to M3R
expression and activation are worthy of further investigation.
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Activation of muscarinic receptors and downstream sig-
naling was shown to stimulate proliferation of cells de-
rived from lung [1,2], breast [3,4], prostate [5], colon
[6,7], and skin [8] cancers, and muscarinic receptors are
frequently over-expressed in these common cancers [9].
Hence, it is highly likely that activation of muscarinic re-
ceptor signaling plays a fundamentally important role in
neoplastic transformation and progression.
Of five cholinergic muscarinic receptor subtypes, desig-
nated M1R – M5R [10], human colon cancer cells express
primarily M3R. M3R activation stimulates cell prolifera-
tion, survival, migration and invasion [6,11-14] – key hall-
marks of neoplasia [15]. Human colon cancer cells also
produce and release acetylcholine at concentrations cap-
able of activating M3R and stimulating cell proliferation,
identifying the capacity for autocrine and paracrine stimu-
lation of M3R signaling [11]. Jointly, these in vitro studies
provided strong evidence that M3R expression and signal-
ing are particularly important in the progression of colon
neoplasia.
Mice with targeted knockout of genes encoding each of
the five muscarinic receptor subtypes (Chrm1 – Chrm5)
are useful for investigating their biological functions
[16-18]. We showed that ablating Chrm3, the gene en-
coding M3R, attenuates colon neoplasia in mice treated
with azoxymethane (AOM), a colon-selective carcinogen
[19]. Compared to AOM-treated WT mice, AOM-treated
Chrm3 knockout mice had 40% and 60% reductions in
tumor number and size, respectively. Similar results were
obtained using Apcmin/+ mice, a genetic model of intestinal
neoplasia [20]. These findings suggested to us that treat-
ments directed at reducing M3R expression, activation or
downstream signaling might be useful to prevent or treat
colon neoplasia. Indeed, Apcmin/+ mice treated with sco-
polamine butylbromide, an inhibitor of muscarinic recep-
tor activation, developed fewer intestinal tumors than
vehicle-treated control mice [20].
Many cell types co-express muscarinic receptor sub-
types [17]. Using in situ hybridization, we demonstrated
expression of mRNA for both M1R and M3R in murine
gastric [21] and colonic [19] epithelial cells. Likewise,
human colon cancer cells used to investigate in vitro ac-
tions of muscarinic receptors and ligands express a mixture
of M3R and M1R, with a predominance of M3R [13,22].
Whereas expression of multiple muscarinic receptor sub-
types in the same cell type is likely to provide growth and
survival advantages, it can also result in complex, unpre-
dictable interactions. This was apparent when we exam-
ined the impact of Chrm1 and Chrm3 co-expression in
gastric chief cells that synthesize and release the pro-
enzyme pepsinogen [21]. M3R deficiency did not alter
carbamylcholine (carbachol)-induced pepsinogen release,
but M1R deficiency resulted in a 25% decrease in pro-enzyme release [21]. Strikingly, in mice deficient in both
M1R and M3R, carbachol-induced pepsinogen secretion
was totally abolished [21].
These observations motivated us to examine the role
of M1R (Chrm1) expression in colon neoplasia and to
determine whether knocking out both M1R (Chrm1)
and M3R (Chrm3) in the same animal (hereafter called
dual KO mice) would more effectively attenuate AOM-
induced colon neoplasia than M3R (Chrm3) knockout
alone. We also took advantage of these murine models
to identify genes whose expression levels might be rele-
vant to resulting colon tumor phenotypes.
Results
Effects of M1R, M3R and dual knockout on murine colon
neoplasia
We treated WT, Chrm3-/-, Chrm1-/- and dual KO mice with
phosphate buffered saline (vehicle control) or AOM, a
colon-selective carcinogen [19] (Figure 1A). As reported
previously [23], at baseline Chrm3-/- mice weighed 15-20%
less than WT mice (Figure 1B). At baseline, Chrm1-/- mice
also weighed less than WT mice, but in contrast to
Chrm3-/- mice, their weights approached those of WT
mice by the end of the 20-week study period (Figure 1B).
As a group dual KO mice were extremely frail, necessi-
tating a modified study design; whereas AOM treatment
was started in six-week-old Chrm3-/- and Chrm1-/- mice,
AOM treatment was delayed in dual KO mice until they
were 11 to 12-weeks-old and better able to tolerate AOM
treatment [24]. Even with this modification, at 11-12
of age dual KO mice weighed ~25% less than WT mice
(Figure 1B), and in contrast to the other genotypes dual
KO mice lost weight during the first six weeks of AOM
treatment; at 20 weeks they still weighed ~30% less than
WT mice (Figure 1B).
Although the gross anatomical appearance of colons in
knockout mice was normal, we detected a modest but sta-
tistically significant reduction in colon length (Figure 1C).
These differences probably reflect the lower body weights
of Chrm3-/-, Chrm1-/- and dual KO compared to WT mice
(Figure 1B). Colon length was not significantly different
when compared within the three groups of knockout
mice. Microscopic review of H&E-stained tissue sections
from untreated (no AOM or vehicle) mice with the four
muscarinic receptor genotypes by a senior gastrointestinal
pathologist (CD) revealed no differences in colon epithe-
lial morphology (Figure 1D).
Mice treated with vehicle alone did not develop colon
neoplasia (not shown). Representative photographs in
Figure 2A show robust colon tumor formation in AOM-
treated mice. At the 20-week end-point, only colons from
Chrm3-/- mice had reduced tumor burden compared to
WT mice (Figure 2A). Tumor measurements revealed 28
and 74% reduction, respectively, in tumor number and
Figure 1 Study protocol, animal weights, colon length and histological appearance of colon sections from mice with different Chrm
genotypes. A: Schematic of study design; WT, Chrm3-/-, Chrm1-/- and dual KO male mice were treated with intraperitoneal injection of AOM
(10 mg/kg) or an equal volume of vehicle (phosphate buffered saline) weekly for 6 weeks and followed for a total of 20 weeks. At 20 weeks,
animals were euthanized and colon tumor number and size, and mucosal markers of proliferation and apoptosis were measured. B: Weights of
AOM-treated mice during the 20-week study (mean ± S.E.). C: Colon length of AOM-treated mice was measured following euthanasia at 20 weeks
(mean ± S.E.). D No morphological differences were seen in hematoxylin and eosin (H&E)-stained microscopic sections of normal colon tissue
from WT, Chrm3-/-, Chrm1-/- and dual KO mice. Size bars = 50 micrometers.
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P < 0.005, respectively) (Figure 2B and C), consistent with
our previous work [19]. When colon tumors were strati-
fied by volume (Figure 2D), a shift in tumor size in
Chrm3-/- mice towards smaller lesions (< 2 mm3) became
evident.
We were surprised to observe that genetic ablation of
Chrm1 did not alter the number or volume of colon tumors
in Chrm1-/- mice compared to WT mice (Figure 2A-D).
Even more surprising were the outcomes in dual KO
mice; tumor number and volume were only slightly
reduced compared to those in WT and Chrm1-/- mice
(Figure 2A-D). That is, concomitant genetic ablation
of Chrm1 in Chrm3-/- mice appeared to mitigate re-
ductions in both colon tumor number and volume
that we repeatedly observed in AOM-treated Chrm3-/-
compared to WT mice (Figure 2A-D) [19].
As shown in Figure 2E, in WT, Chrm1-/- and dual KO
mice the majority of colon tumors were adenocarcin-
omas. In contrast, Chrm3-/- mice had nearly equivalent
numbers of adenomas and adenocarcinomas. Although
adenomas were numerically less frequent in dual KO
compared to WT mice (Figure 2E), this was not a sig-
nificant difference (P = 0.1). Likewise, there were no sig-
nificant differences in the numbers of adenocarcinomasper section when comparing Chrm1-/-, dual KO and WT
mice. Conversely, the 76% reduction in adenocarcinomas
in colons from Chrm3-/- compared to WT mice was highly
significant (P < 0.001) (Figure 2E). These findings suggest
that the major impact of M3R deficiency in AOM-treated
mice is to block progression of colon adenomas to
adenocarcinomas.
We evaluated the multiplicity of adenocarcinomas per
section; 56% of Chrm3-/- mouse colons had no adenocar-
cinomas and only one Chrm3-/- mouse had more than
one colon adenocarcinoma. In contrast, more than 50%
of WT, Chrm1-/- and dual KO mice had multiple (two to
seven) adenocarcinomas per section and only two of 20
WT (10%) and one of 12 dual KO (8%) mice had no
adenocarcinomas (P < 0.01 for reduced multiplicity of
tumors in colons from Chrm3-/- mice vs. colons from
the other three genotypes). Colons from all Chrm1-/- mice
contained at least one adenocarcinoma.
We considered the possibility that modifying our
protocol to delay AOM treatment of frail dual KO mice
until they were 12 weeks old might have impacted out-
comes – AOM treatment in the three other genotypes
started when mice were six weeks old. To exclude this as
a confounder, we started AOM treatment in WT mice at
six (N = 25) or 12 (N = 16) weeks of age. Twenty weeks
Figure 2 Measurement of colon tumor number and size 20 weeks after starting AOM treatment. A: Representative photographs of
resected distal colon from AOM-treated mice with different Chrm genotypes. B: Tumor number was reduced in AOM-treated Chrm3-/- compared
to WT mice (P < 0.05). There was no significant difference in tumor number in Chrm1-/- and dual KO compared to WT mice (mean ± S.E.).
C: Reduced tumor volume in Chrm3-/- compared to WT mice (P < 0.005). Tumor volume in Chrm1-/- and dual KO compared to WT mice was not
significantly different (mean ± S.E.). D: Histogram of tumor volume in AOM-treated WT, Chrm3-/-, Chrm1-/- and dual KO mice. E: Numbers of adenomas
and adenocarcinomas per section in AOM-treated WT, Chrm3-/-, Chrm1-/- and dual KO mice.
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in tumor number or volume when comparing mice
that started AOM treatment at age six versus 12 weeks
(Additional file 1). We concluded that the failure to ob-
serve reduced tumor number and size in AOM-treated
dual KO mice cannot be attributed to the delay in initiat-
ing AOM treatment.
Effect of M1R, M3R and dual knockout on tumor cell
proliferation and apoptosis
To determine whether changes in tumor number and
size resulted from differences in cell proliferation and
apoptosis, we examined Ki67 and activated caspase-3
staining, respectively. Figure 3A shows representative
micrographs of Ki67 staining in adenomas from AOM-
treated WT, Chrm3-/-, Chrm1-/- and dual KO mice.
Compared to adenomas from AOM-treated WT mice,
Ki67 staining was significantly reduced in those from
Chrm3-/- and dual KO but not Chrm1-/- mice (Figure 3).
Figure 3B shows 58% reduction in Ki67-positive cells inadenomas from Chrm3-/- compared to those from WT
mice (P < 0.01). Ki67 staining was reduced 42% in dual
KO mice (P < 0.05 compared to WT mice). Thus, al-
though Ki67 staining was significantly reduced in dual
KO compared to WT mice, this reduction was less than
that observed in Chrm3-/- mice (Figure 3B), suggesting
that in AOM-treated mice concomitant ablation of
Chrm1 mitigates anti-proliferative effects of Chrm3 gene
ablation.
Figure 3C shows representative micrographs of acti-
vated caspase-3 staining in adenomas from AOM-
treated WT, Chrm3-/-, Chrm1-/- and dual KO mice. The
number of apoptotic cells in adenomas from AOM-
treated mice was almost two orders of magnitude lower
than the number of proliferating cells (compare scales for
vertical axes in Figure 3B and D). Apoptotic cells were re-
duced in adenomas from Chrm3-/- and dual KO compared
to WT mice (P < 0.01 and < 0.001, respectively). In con-
trast, apoptotic cells were not significantly different in
adenomas from Chrm1-/- and WT mice (Figure 3D).
Figure 3 Markers of cell proliferation and apoptosis in colon adenomas from AOM-treated mice. A. Representative staining for Ki67 in
adenomas from WT, Chrm3-/-, Chrm1-/- and dual KO mice. B. Ki67 staining was significantly reduced in adenomas from Chrm3-/- and dual KO
compared to WT mice. C. Representative staining for activated caspase-3 in adenomas from WT, Chrm3-/-, Chrm1-/- and dual KO mice. Stained cells
are indicated by arrows. D. Activated caspase-3 staining was significantly reduced in adenomas from Chrm3-/- and dual KO compared to WT mice.
For B and D, N = 22 WT, 19 Chrm3-/-, 23 Chrm1-/- and 12 dual KO mice. Size bars = 200 micrometers.
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and Chrm3-/- mice
Tissues obtained in these experiments provided an op-
portunity to identify novel genes and signaling pathways
potentially underlying tumor-promoting actions of M3R
activation in the colon [6,11-14]. We designed an experi-
mental strategy using gene microarray to compare gene
expression profiles in tumors from Chrm3-/- and WT mice,
and thereby identify novel candidate M3R-regulated genes
worthy of further exploration. To exclude changes in gene
expression that resulted from neoplastic transformation
but were not a specific consequence of changes in M3R
expression, we used qPCR to validate key microarray find-
ings and compare expression of candidate genes in tumors
from Chrm3-/-, Chrm1-/-, dual KO and WT mice. We rea-
soned that genes whose expression levels were different in
tumors from Chrm3-/- compared to WT mice, but not in
tumors from Chrm1-/- compared to WT mice, would
more likely be relevant to M3R-induced colon tumor pro-
motion. Although this approach has potential limitations
we thought it would provide useful information regarding
potential molecular pathways underlying the different
tumor phenotypes.
We used an Illumina gene microarray to compare ex-
pression profiles for 19,100 genes in tumors from Chrm3-/-and WT mice. Using 474 probes, we identified 430 genes
either up- or down-regulated by enrichment scores of at
least 1.3 (equivalent to a non-log scale value of 0.05) in tu-
mors from AOM-treated Chrm3-/- mice compared to
those from WT mice. Ingenuity Pathway Analysis of this
data set did not reveal involvement of a known pathway to
explain tumor attenuation in AOM-treated Chrm3-/- com-
pared to WT mice (data not shown).
Surmising that M3R-regulated genes important for
colon tumor promotion would undergo relatively large
changes in expression, for further analysis we arbitrarily
set a cut-off at the top 14 down-regulated and top 14
up-regulated genes identified by microarray in tumors
from Chrm3-/- compared to WT mice, a total of 28
genes (Figure 4A). The heat map deriving from this ‘valid-
ation set’ demonstrates consistent changes in gene expres-
sion in tumors from three mice from each genotype.
There were large changes in expression of some genes.
Fcer1g gene expression was nearly abolished in tumors
from Chrm3-/- compared to those from WT mice whereas
Tmem14C gene expression was strongly up-regulated
(Figure 4A), findings confirmed by qPCR using the same
mRNA employed for the microarray analysis (not shown).
We used qPCR to examine expression of a subset of
genes strongly associated with colon neoplasia [25]. Cyclin
Figure 4 Analyses of gene expression in tumors from WT and Chrm3-/- mice. A: Heat map displaying expression pattern of the 28 genes
with the largest changes in expression when comparing tumors from Chrm3-/- relative to tumors from WT mice. Rows represent genes and
columns represent samples. Color intensity denotes the standardized ratio between each value and the average expression of each gene across
all samples. Red pixels indicate increased abundance and green pixels decreased abundance of each transcript in the indicated sample. N = 3
mice/ genotype. B: Comparison of changes in murine gene expression levels in tumors from Chrm3-/- mice relative to tumors from WT mice
quantified by real time RT-PCR (qPCR). WT, wild-type.
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mice compared to those from WT mice suggesting that
changes in some genes key to intestinal neoplasia oc-
curred prior to the 20-week end-point (Additional file 2).
Nonetheless, at the 20-week time-point, expression of
both c-myc and β-catenin in tumors from Chrm3-/- com-
pared to those from WT mice was reduced 25%, and
Myd88 expression was reduced 32% (Additional file 2).
The greatest changes were in Egfr and Cox2 expression, re-
duced 54 and 70%, respectively, in tumors from Chrm3-/-
mice (Additional file 2). Altered Egfr expression was of par-
ticular interest since we showed previously that cross-talk
between M3R and EGFR is critical for human colon cancer
cell proliferation [6] and others showed that Egfr signaling
in mice is required for AOM-induced colon neoplasia
[26,27]. COX2 is also over-expressed in human colon neo-
plasia [28,29] and, in mouse models of intestinal neoplasia,
Cox2 (Ptgs2)-deficiency attenuates tumor formation [30].
We also confirmed the absence of compensatory increases
in Chrm3 expression in Chrm1-/- mice that could account
for the Chrm1-/- colon tumor phenotype.
To validate changes in expression of the 28 genes shown
in Figure 4A, we extracted additional mRNA from colon
tumors from WT and Chrm3-/- mice and compared gene
expression using qPCR. To more effectively separate sig-
nal from noise, for this analysis we selected an arbitrary
conservative threshold of two-fold or greater changes in
mRNA expression. Applying these more stringent criteria,we detected meaningful changes in the expression of
mRNA for 14 genes derived from the original 28-gene set
(Figure 4A); eight genes were down-regulated and six were
up-regulated in tumors from Chrm3-/- compared to WT
mice (Figure 4B). To our knowledge, none of the 14 genes
in this ‘core Chrm3-dependency gene set’ were previously
associated with muscarinic receptor signaling.
Comparison of gene expression in colon tumors from
Chrm3-/-, Chrm1-/-, dual KO and WT mice
To identify novel genes relevant to Chrm subtype-dependent
differences in colon neoplasia, we used qPCR to measure
expression of the core Chrm3-dependency gene set shown
in Figure 4B using mRNA extracted from tumors from
Chrm3-/-, Chrm1-/- and dual KO mice, and then compared
expression of these 14 genes to that in tumors from WT
mice. Specifically, we sought genes whose expression
levels in tumors from Chrm3-/- and Chrm1-/- mice com-
pared to those from WT mice were consistent with the
different colon neoplasia phenotypes (Figure 2B and C);
that is, we thought it important to pursue genes with
meaningful changes in expression in tumors from
Chrm3-/- compared to WT mice, but not in tumors from
Chrm1-/- compared to WT mice. Using this approach we
identified five candidate mouse genes meeting these cri-
teria - Tpmt, Prcp, Pmp22, Nanos1 and Zfp277. One gene
(Tpmt) was up-regulated in tumors from Chrm3-/- mice
and four (Prcp, Pmp22, Nanos1 and Zfp277) were down-
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expression that achieved statistical significance was re-
duced Zfp277 levels in tumors from Chrm3-/- compared to
those from WTand Chrm1-/- mice (P < 0.05, Figure 5A).
Next, to determine whether similar changes in gene
expression occurred in non-neoplastic colon, we used
qPCR to compare expression levels of these five candidate
genes in normal colon from WT, Chrm3-/-, Chrm1-/- and
dual KO mice that had not been treated with either AOM
or vehicle (Figure 5B). In these experiments, we used ex-
pression of an endogenous housekeeping gene, Gapdh, as
an internal control; Gapdh expression did not change sig-
nificantly in normal colon and tumors across mouse geno-
types (not shown). Comparison of the data in Figure 5A
and B revealed similar patterns of gene expression in tu-
mors and normal colon tissue for Prcp, Pmp22, Nanos1
and Zfp277, but not for Tpmt. Hence, we considered it
likely that changes in expression of mRNA for Tpmt in tu-
mors resulted from neoplastic transformation irrelevant to
regulation by muscarinic receptor signaling; Tpmt was ex-
cluded from further consideration. Again, the only change
in gene expression achieving statistical significance was
reduced Zfp277 levels in normal colon from Chrm3-/-
compared to expression in normal colon from WT and
Chrm1-/- mice (P < 0.05, Figure 5B). Based on these col-
lective findings, we selected Zfp277 for further analysisFigure 5 Expression levels of murine genes quantified by qPCR in tum
tumor sections from WT, Chrm3-/-, Chrm1-/- and dual KO mice. A: Colo
Shown is the fold difference in gene expression normalized to glyceraldeh
Chrm1-/- and dual KO mice relative to that in tissue from WT mice. Error bars, S.E.
staining with anti-Zfp277 antibody on tumor sections from WT, Chrm3-/-, Chrm
tumor sections. Data shown represent mean ± S.E. from four mice per genotyand excluded Tpmt, Prcp, Pmp22 and Nanos1 from fur-
ther consideration as genes relevant to M3R-regulated
colon neoplasia.
Zinc finger protein 277 expression in tumors from WT,
M1R- and M3R-deficient mice
To establish the functional relevance of changes in gene
expression, we used immunohistochemistry with specific
antibodies to interrogate colon tumor sections for changes
in Zfp277 protein expression corresponding to changes in
Zfp277 mRNA levels. In colon tumors from WT mice we
observed robust Zfp277 staining (Figure 5C). Notably,
Zfp277 protein expression was reduced approximately
50% in tumors from Chrm3-/- and dual KO mice com-
pared to tumors from WT mice (P < 0.05) (Figure 5C). As
anticipated from the mRNA data, Zfp277 protein expres-
sion was the same in tumors from WT and Chrm1-/- mice
(Figure 5C). Taken together, these novel findings iden-
tify parallel changes in both gene and protein expression
for Zfp277.
Zinc finger protein 277 is over-expressed in human colon
cancer
As an initial exploration of the potential clinical signifi-
cance of these findings, we searched human expression
data sets in the National Center for Biotechnologyor and normal colon tissue, and Zfp277 protein expression in
n tumors. N = 3 mice/genotype. B: Normal colon. N = 3 mice/genotype.
yde-3-phosphate dehydrogenase (Gapdh) levels in tissue from Chrm3-/-,
(* indicates P< 0.05). C: Representative images show immunohistochemical
1-/- and dual KO mice. Graph shows quantification of Zfp277 staining in
pe (* indicates P < 0.05). Size bars = 100 micrometers.
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Profiles database. Specifically, in datasets of human
colon cancer compared to adjacent normal colon tissue
from the same person we sought information regarding
the expression of ZNF277, the human analogue of
Zfp277. This database search yielded only one relevant
study of surgical specimens comparing gene expression
profiles in colon cancer compared to normal colon [31].
Our in silico analysis of this existing dataset revealed
that ZNF277 expression was significantly up-regulated
in 33 of 34 colon cancers compared to adjacent normal
colon (P = 2 × 10-8) [31].
We sought to confirm this observation in our lab by
interrogating a set of 12 archived colon cancer tissues
with adjacent normal colon that had been flash-frozen
immediately after surgery at our own institution and
stored at -80°C. In Figure 6A, changes in mRNA expression
in colon cancer compared to normal colon are depicted inFigure 6 M3R and ZNF277 gene and protein expression in human co
ZNF277 mRNA levels in 12 sets of colon cancer and adjacent normal colon
to expression of β2-microglobulin and then ranked by increasing levels of CHR
staining with anti-ZNF277 and anti-M3R antibodies on human colon cancer a
C: Graph shows quantification of ZNF277 and M3R staining in cancer compar
cancer and adjacent normal colon tissues.order of increasing CHRM3 expression (black bars). Al-
though increases in ZNF277 mRNA were not as robust as
those for CHRM3 mRNA, the expression patterns were
very similar (Figure 6A). In these 12 human tissue sam-
ples, over-expression of ZNF277 in colon cancer was con-
tingent upon over-expression of CHRM3 (Spearman rank
correlation coefficient = 0.73).
Next, we validated the importance of these changes in
gene expression by measuring and comparing M3R and
ZNF277 protein expression in an archived set of 23
formalin-fixed paraffin-embedded colon cancer tissues
with adjacent normal colon from the same patients. We
analyzed these samples immunohistochemically using
specific antibodies for M3R and ZNF277 (Figure 6B). As
shown in Figure 6C, zinc finger protein 277 and M3R
were both significantly over-expressed in cancer com-
pared to adjacent normal tissue. Moreover, as we ob-
served for gene expression, statistical analysis of theselon cancer compared to adjacent normal colon. A: CHRM3 and
obtained from the same patients. mRNA levels were first normalized
M3 expression. B: Representative images show immunohistochemical
nd adjacent normal colon epithelial tissue. Size bars = 100 micrometers.
ed to normal colon. Data shown represent mean ± S.E. of 23 sets of colon
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ZNF277 and M3R protein were also contingent vari-
ables; i.e., ZNF277 over-expression was statistically asso-
ciated with M3R over-expression (P = 0.04). Collectively,
these data support the novel conclusion that in both
murine and human colon cancer, zinc finger protein 277
plays a currently undefined role in M3R-mediated pro-
motion of neoplasia.
Discussion
Experimental mouse models that mimic clinical and mo-
lecular aspects of human colon cancer progression are
useful tools to identify novel mechanisms underlying
colon neoplasia [24]. Here, to explore the individual
roles and interplay between two muscarinic receptor sub-
types, we analyzed systematically the effects of Chrm3
and Chrm1 gene ablation, alone and in combination,
on AOM-induced murine colon neoplasia, a model closely
resembling non-hereditary human colon cancer [24]. To
gain additional genetic and potentially mechanistic in-
sights, we used a hypothesis-unbiased approach to eluci-
date concomitant changes in gene expression levels in
tumors from WTand M3R-deficient mice.
As anticipated from our previous work [19,20], tumor
number and size as well as tumor cell proliferation mea-
sured by Ki67 staining were greatly attenuated in AOM-
treated Chrm3-/- compared to WT mice. Based on our
previous findings regarding the interplay of M1R and
M3R in gastric function [21], we hypothesized that com-
pared to the effects of Chrm3 gene ablation alone, con-
current ablation of Chrm3 and Chrm1 might further
attenuate, or even abolish, AOM-induced tumor forma-
tion. Instead, we were surprised to observe that Chrm1
gene ablation alone did not alter tumor formation. We
were further surprised to observe that combined Chrm3
and Chrm1 knockout mitigated reductions in tumor
number and size observed with Chrm3 knockout alone.
We can draw several novel conclusions from these
observations. Whereas work from our [19] and other
groups [2-4,7,8] provide strong evidence that M3R acts as
a tumor promoter, the present observations newly suggest
that in the colon M1R acts as a tumor suppressor. This
putative role for M1R is unmasked by combined M1R and
M3R deficiency in dual KO mice where tumor formation
is similar to that observed in WT mice. Thus, M1R defi-
ciency appears to negate the beneficial effects of knocking
out only M3R. This finding may also explain why treating
Apcmin/+ mice with a non-selective muscarinic receptor
inhibitor, scopolamine butylbromide, attenuates intestinal
tumor formation less efficaciously than M3R gene abla-
tion [20]. Scopolamine butylbromide treatment blocks
both M3R and M1R activation, thereby mimicking
combined M3R and M1R deficiency in dual KO mice.
These considerations intimate therapeutic promise fora pharmacological approach to block M3R activation while
at the same time augmenting M1R activation.
The unanticipated findings regarding the impact of
Chrm3 and Chrm1 knockout on AOM-induced colon neo-
plasia provided an opportunity to explore M3R-regulated
changes in tumor gene expression. We identified a set
of genes expressed differentially in tumors from WT
and M3R-deficient mice. Then, we used tumors from
M1R-deficient mice as controls to exclude non-specific
changes in gene expression due to neoplastic transform-
ation but not a specific consequence of altered M3R
expression. We employed a gene microarray compris-
ing 19,100 target genes to identify 430 genes with
expression levels significantly altered in tumors from M3R-
deficient compared to WT mice (strategy schematized in
Additional file 3); a dataset further refined by increasing
statistical stringency and using qPCR to validate results.
These combined approaches identified 14 promising genes
with meaningful changes in expression in tumors from
M3R-deficient compared to WT mice (Figure 4B).
We concede this gene discovery approach has limita-
tions. It may have identified only a fraction of the genome;
many genes are turned off or encode proteins required for
survival in specific amounts that do not change. Also, pro-
tein expression may be regulated by mechanisms that do
not involve altered mRNA levels. Financial constraints
limited expression profiling experiments to a relatively
small number of observations under identical conditions
and for the same reason limited further investigation of
candidate genes to the relatively small subset of 14 genes
shown in Figure 4B, thereby reducing statistical power.
We may have missed important but subtle changes in
gene expression. Even so, we believe that confirmatory
results from our qPCR experiments provided reliable
measures of changes in the expression levels of this 14-
gene subset in both tumors and normal colon from WT,
Chrm3-/-, Chrm1-/- and dual KO mice.
Changes in expression of only one gene, Zfp277,
achieved statistical significance with matching changes
in expression of the corresponding protein. Based on the
stringent overall approach (Additional file 3), we are
confident that our work identifies a novel role for Zfp277
as an M3R-regulated gene pertinent to the progression of
intestinal neoplasia. Confidence in this conclusion was
bolstered by detecting over-expression of both mRNA and
protein for ZNF277, the human analogue of Zfp277, in
human colon cancer samples and, importantly, that this
over-expression mirrored that of CHRM3 and M3R.
Literature and gene bank searches revealed little regard-
ing the function of ZNF277 (NIRF4), which is expressed in
multiple tissues, including the proximal colon [32]. The
protein product, zinc finger protein 277, is reported to play
a role in cellular senescence and protection against gen-
omic instability and cancer [33]. ZNF277 over-expression
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leukemia, well-differentiated renal cell carcinoma, and
germ cell and endocrine tumors [32]. Hence, a novel,
hitherto unrecognized role for ZNF277 in colon can-
cer biology is certainly plausible. We found no previ-
ous reports of an association between either Zfp277
or ZNF277 expression and muscarinic receptor ex-
pression or activation. In future work, we plan to use
in vitro and in vivo models to explore the molecular
mechanisms underlying the association between M3R
and ZNF277 expression.
Conclusions
Our results identify a novel candidate mouse gene,
Zfp277, whose expression pattern is compatible with a
role in mediating divergent effects of Chrm3 and Chrm1
gene ablation on murine intestinal neoplasia. Although
finding an association between ZNF277 and M3R over-
expression in human colon cancer is reassuring, we do
not currently understand the molecular mechanism
underlying this interaction. Future work will use both
in vitro and in vivo approaches to address these ques-
tions and elucidate the functional role of ZNF277 and its
interaction with M3R in colon cancer. Although it is
currently unclear why M3R and M1R, which both signal
by stimulating phospholipid turnover and changes in cell
calcium [10], have such divergent effects on colon neo-
plasia, their contrary roles suggest that jointly targeting
these receptors may have therapeutic potential. Based on
these considerations, we are optimistic that improved
understanding of the role of muscarinic receptors in




Chrm3-/- and Chrm1-/- mice were generated from the same
mixed genetic background (129S6/SvEvTac X CF1: 50%/
50%) as described previously [23,34,35]. Dual KO mice on
the same genetic background were generated by mating
homozygous Chrm1-/- and Chrm3-/- mutant mice [36].
For all experiments, only male mice were used and aged-
matched WT mice of the same genetic background served
as controls. Mice were housed under identical conditions in
a pathogen-free room, had free access to commercial rodent
chow and water, and were acclimatized in the vivarium for
at least one week before experiments. These studies were
approved by the University of Maryland School of Medicine
Institutional Animal Care and Use, and the Baltimore VA
Research and Development Committees.
Human tissues
To examine M3R (CHRM3) and ZNF277 gene and protein
expression, we used archived pre-existing de-identifiedsurgical specimens of colon cancer and adjacent normal
colon epithelium (approved by the University of Maryland
School of Medicine Institutional Review Board and the
Baltimore VA Research and Development Committee).Study design
For the initial 6 weeks of treatment, 94 mice (25 WT, 20
Chrm3-/-, 23 Chrm1-/- and 26 dual KO mice) received
weekly intraperitoneal injections of azoxymethane (AOM;
Midwest Research Institute; 10 mg/kg body weight) and
21 mice (5 WT, 5 Chrm3-/-, 5 Chrm1-/- and 6 dual KO
mice) received an equal volume of vehicle (phosphate-
buffered saline) (Figure 1A). As in our previous study
[19], AOM and vehicle treatment in WT, Chrm3-/- and
Chrm1-/- mice was started when animals were 6-weeks
old. In dual KO mice, AOM and PBS treatments were ini-
tiated at 12 weeks of age. All animals were euthanized
20 weeks after initiating AOM injections. Colon length
was measured, and segments were opened longitudinally
and placed flat on microscope slides. Tumors were
identified by visual inspection and photographed (Nikon
SMZ1500 dissecting microscope). Tumor size was mea-
sured using calipers and tumor volume calculated using:
volume = ½ (length × width2) [37].Histological and immunohistochemical staining analysis
Tissues were fixed in 4% paraformaldehyde and paraffin-
embedded. Five-micrometer sections were stained with
hematoxylin and eosin. Adenomas and adenocarcinomas
were defined according to consensus recommendations
by the Mouse Models of Human Cancers Consortium
[38]. As markers of cell proliferation and apoptosis,
we used immunohistochemical staining for Ki67 and
activated caspase-3, respectively (antibodies from Cell
Signaling Technology). Only complete crypts were eval-
uated and investigators were masked to genotype and
treatment group.
To identify corresponding changes in protein expres-
sion for relevant genes identified by microarray and
qPCR, formalin-fixed paraffin-embedded tumor sections
were immunostained with a specific antibody against
both mouse Zfp277 and human ZNF277 from Santa
Cruz Biotech (Santa Cruz, CA), and a specific antibody
from Alomone Labs (Jerusalem, Israel) against both
mouse and human M3R. Tumor sections were examined
with a Nikon 80i photomicroscope at 200× magnifica-
tion. Sections were first reviewed and scored by a senior
pathologist (CD) masked to tissue origin and immu-
nostaining was then quantified using Image-Pro Plus
software (version 5.1; Media Cybernetics, Silver Spring,
MD). To minimize variation, all tumor sections were
examined and photographed using the same micro-
scope settings.
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After resection, murine tissue was immediately stored in
RNAlater (Ambion) at -80°C. Total RNA was extracted
using the RNeasy kit from Qiagen. RNA was digested
using the RNase-Free DNase set. The quality of total
RNA was tested and confirmed using a Bioanalyzer 2100
(Expression Analysis, Inc., Durham, NC). The microarray
assay was performed by Expression Analysis, Inc. using
the MouseWG-6 v2.2 Expression BeadChip (Illumina, San
Diego, CA). This chip covers the whole mouse genome, >
19,100 unique, curate genes targeting a total of 45,281
transcripts. Results were analyzed using the cubic spline
normalization method without background subtraction
[39,40]. In comparing changes in mRNA expression in
Chrm3-/- vs. WT mouse colon tumors, statistical signifi-
cance cutoff levels were set for individual transcripts at
P ≤ 0.05 (false discovery rate) and enrichment scores ≥ ±
1.3; changes in gene mRNA that met these thresholds
were deemed to be differentially expressed. Microarray
data represent results of tissue from three different mice
per genotype. Results were submitted to the National
Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) database (GSE43444).
Quantitative RT-PCR (qPCR)
First-strand cDNAs were synthesized from 5 μg RNA
(Superscript III First Strand Synthesis System for RT-
PCR, Invitrogen). qPCR was then performed using 50 ng
cDNA, the SYBR Green PCR Master Mix (Applied Bio-
systems), and forward and reverse primers (final concen-
tration 0.5 μM in sample volumes of 20 μl). Primers
(Additional file 4) were designed to span introns using
the National Center for Biotechnology Information nu-
cleotide database SIM-4 gene alignment program and
on-line software (http://www.genscript.com/index.html).
qPCR was performed using the 7900HT Fast System
(ABI) with Power SYBR Green Master Mix (ABI). PCR
conditions included 5 min at 95°C followed by 37 cycles
of 95°C for 15 seconds, 60°C for 20 seconds, and 72°C
for 40 seconds and a final cycle at 95°C for 15 seconds,
60°C for 15 seconds, and 95°C for 15 seconds. PCR data
were analyzed using ABI instrument software SDS 2.1.
Expression of candidate genes in each group of
mice was normalized to glyceraldehyde 3-phosphate
dehydrogenase (Gapdh). For human samples, expres-
sion of CHRM3 and ZNF277 was normalized to
β2-microglobulin (B2M), a preferable housekeeping gene
for analysis of colon cancer [41]. Quantitative qPCR data




Student’s unpaired t-test was used to determine statistical
significance. The strength of linear association betweentwo variables was quantified using the Spearman’s rank
correlation coefficient and that of non-linear associations
by Pearson’s chi-squared test. P values ≤0.05 were consid-
ered significant.
Additional files
Additional file 1: Delaying initiation of AOM treatment until mice
are 12-weeks-old rather than 6-weeks-old does not alter colon
tumor number. Comparison of tumor number (left panel) and tumor
volume (right panel) 20 weeks after starting AOM treatment in 6- and
12-week-old WT mice (mean ± S.E.). N represents number of mice per
treatment group.
Additional file 2: Comparison of changes in expression of key
genes associated with colon neoplasia in tumors from Chrm3-/-
mice relative to tumors from WT mice quantified by real time
RT-PCR (qPCR).
Additional file 3: Experimental strategy used to identify changes in
gene and protein expression relevant to divergent effects of
muscarinic receptor gene ablation on colon neoplasia phenotypes.
The experimental approaches, comparators and yields (outcomes) for
each stage of investigation are outlined. An enrichment score of 1.3 is
equivalent to a non-log scale value of 0.05. qPCR, quantitative RT-PCR;
WT, wild-type; IHC, immunohistochemical analysis.
Additional file 4: RT-PCR (qPCR) primers used in this study.
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